Class action complaint against Prilosec OTC
This article was originally published in The Tan Sheet
Executive SummaryAn Ohio man claims he and hundreds of others suffered food-borne illnesses as a result of taking the proton pump inhibitor and because drug originator AstraZeneca and marketer Procter & Gamble "intentionally and uniformly hid from consumers" evidence of the side effect. Thomas Mitchell says in the complaint filed May 29 in the U.S. District Court for the Southern District of Ohio, Eastern Division, that he became ill after meals while taking Prilosec OTC. A P&G spokesman said in an e-mail that FDA "did not recommend any labeling regarding a link between Prilosec OTC and food poisoning" during the Rx-to-OTC switch review process
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.